[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Promis Neurosciences Inc (PMN)

Promis Neurosciences Inc (PMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,354
  • Shares Outstanding, K 8,968
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,720 K
  • EBIT $ -41 M
  • EBITDA $ -41 M
  • 60-Month Beta -0.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.09
  • Number of Estimates 1
  • High Estimate $-2.09
  • Low Estimate $-2.09
  • Prior Year $-7.25
  • Growth Rate Est. (year over year) +71.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.31 +8.59%
on 05/08/26
11.49 -12.01%
on 05/06/26
-0.90 (-8.17%)
since 05/01/26
3-Month
9.31 +8.59%
on 05/08/26
27.40 -63.10%
on 03/05/26
-12.68 (-55.64%)
since 03/02/26
52-Week
6.27 +61.24%
on 11/28/25
39.75 -74.57%
on 07/21/25
-2.39 (-19.12%)
since 06/02/25

Most Recent Stories

More News
ProMIS Neurosciences to Participate in Upcoming Conferences in June

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS’ landmark  Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque  ProMIS on track to complete enrollment in PRECISE-AD trial...

PMN : 10.13 (-2.69%)
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new...

PMN : 10.13 (-2.69%)

Business Summary

ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330,...

See More

Key Turning Points

3rd Resistance Point 11.64
2nd Resistance Point 11.39
1st Resistance Point 10.90
Last Price 10.13
1st Support Level 10.16
2nd Support Level 9.91
3rd Support Level 9.42

See More

52-Week High 39.75
Fibonacci 61.8% 26.96
Fibonacci 50% 23.01
Fibonacci 38.2% 19.06
Last Price 10.13
52-Week Low 6.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.